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Correspondence
In the letter by O’Brien et al. [Environ Health Perspect 117:A385–386 (2009)], the 
competing financial interest declaration was incorrect. The correct declaration is as follows:
Karen Peabody O’Brien is executive director of Advancing Green Chemistry, a not-for-profit 
organization that receives support from several private foundations (listed online at http://www.
AdvancingGreenChemistry.org/AdvancingGreenChemistry/About_Us.html) to support efforts 
to build the field of green chemistry. J.P. Myers is founder, chief executive officer, and chief sci-
entist for Environmental Health Sciences (EHS), a not-for-profit organization that receives sup-
port from several private foundations (listed online at http://www.environmentalhealthnews.org/
about.html) to support EHS’s mission to advance public understanding of environ  mental health 
sciences. John Warner is president of Warner Babcock Institute for Green Chemistry, a private 
company that applies the principles of green chemis  try in the synthesis of new materials and the 
  redesign of chemical processes.
In the letter by Wilson and Schwarzman [Environ Health Perspect 117:A386 (2009)], 
the last sentence in the first paragraph was incorrect. The corrected sentence is as 
  follows: 
We would add that public policy that accurately reflects current science—and the needs of 
the chemicals market—is instrumental to the widespread adoption of green chemistry.
EHP apologizes for the error.
In the article by La Merrill et al. [Environ Health Perspect 117:1414–1419 (2009)], the keys 
in Figure 3B and Figure 5C should have been in Figure 3C and Figure 5D, respectively. The 
corrected figures are provided below.
EHP apologizes for the errors.
In the article by Alyea and Watson [Environ Health Perspect 117:778–783 (2009)], the x-axis labels in Figure 2 were incorrect. 
The corrected figure appears below. 
EHP apologizes for the error.
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Figure 2. Concentration-dependent dopamine efflux patterns for E2 and XEs 
at 9 (A) and 5 min (B), using optimal time points for each compound chosen 
from the 10–9 M time course (Figure 1). (A) A 9-min dopamine efflux for E2, 
DES, endosulfan, DDE, NP, and BPA at concentrations ranging from 10–14 to 
10–9 M. (B) A 5-min dopamine efflux for E2, dieldrin, NP, and BPA at concen-
trations ranging from 10–14 to 10–9 M. Values are means and SEs; numbers 
per treatment are as follows: E2, n = 18; dieldrin, n = 12; DES, n = 18; endosul-
fan, n = 12; DDE, n = 12; BPA, n = 23; NP, n = 15. Points above the zero point 
line indicate a positive efflux of dopamine from the cells. 
*p < 0.05 compared with control. #p < 0.05 compared with E2 treatment. 